Mercury guides OID at 98.5 as arrangers opt for caution
Arranging banks appear to be steering clear of pushing investors too far over leveraged loan pricing as the latest deal in the market — the loan backing Cinven’s buyout of Mercury Pharma — guided its original issue discount to 98.5 at a bank meeting on Wednesday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
